GENB Company Profile and Key Details

NASDAQ : GENB

Generate Biomedicines

$15.18

0.805+5.60%

Open: 12:45 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Generate Biomedicines, Inc. (GENB) stock surged +5.60%, trading at $15.18 on NASDAQ, up from the previous close of $14.37. The stock opened at $14.42, fluctuating between $14.42 and $15.63 in the recent session.

Stock Snapshot

14.37

Prev. Close

1.93B

Market Cap

14.42

Day Low

-7.3

P/E Ratio

-2.08

EPS (TTM)

N/A

Cash Flow per Share

14.42

Open

127.45M

Number of Shares

15.63

Day High

N/A

Free Float in %

N/A

Book Value

147.16K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 11, 2026	13.65	14.95	13.46	14.37	358.82K
May 08, 2026	13.79	14.65	13.36	13.66	291.57K
May 07, 2026	14.78	15.40	13.55	13.59	318.05K
May 06, 2026	15.42	15.89	14.82	15.30	201.31K
May 05, 2026	14.52	15.47	14.42	15.42	289.69K
May 04, 2026	13.02	14.92	12.78	14.46	339.5K
Apr 30, 2026	12.51	13.15	12.51	12.63	202.26K
Apr 29, 2026	12.47	12.80	12.03	12.38	283.56K
Apr 28, 2026	12.45	12.90	12.31	12.47	352.73K
Apr 27, 2026	12.90	13.45	12.21	12.45	258.01K
Apr 23, 2026	12.88	13.09	12.66	12.86	323.07K
Apr 22, 2026	12.50	13.05	12.47	13.03	329.38K
Apr 21, 2026	12.18	12.76	11.84	12.67	620.32K
Apr 20, 2026	12.45	12.48	12.00	12.12	447.25K
Apr 17, 2026	12.61	12.89	12.24	12.45	270.95K
Apr 16, 2026	12.60	12.88	12.35	12.61	290.79K
Apr 14, 2026	13.03	13.36	12.63	12.89	366.09K
Apr 13, 2026	11.73	12.98	11.50	12.80	373.69K
Apr 10, 2026	11.69	11.73	11.10	11.41	345.82K
Apr 09, 2026	12.00	12.14	11.43	11.53	204.04K

Contact Details

Somerville, MA 02143

United States

https://generatebiomedicines.com 188 846 90055

About Company

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts.

Stock Peers

RYSIX

23.26+2.48%

Rydex Electronics Inv$962.40 WFSPX

1.69+0.20%

iShares S&P 500 Index K$863.02 BSPIX

1.68+0.20%

iShares S&P 500 Index Fund Institutional Shares$862.74 BSPAX

1.67+0.19%

iShares S&P 500 Index Fund Investor A Shares$862.36 QQQ

2.06+0.29%

Invesco QQQ Trust, Series 1$713.29 VFINX

1.33004+0.19%

Vanguard 500 Index Fund$684.79 VFIAX

1.34006+0.20%

Vanguard 500 Index Fund Admiral Shares$684.72 SSEYX

1.35+0.20%

State Street Equity 500 Index II$669.67 MUU

70.87+13.06%

Direxion Daily MU Bull 2X ETF$613.59 VIIIX

1.17+0.20%

Vanguard Institutional Index Fund Institutional Plus Shares$594.00

Company Overview

Generate Biomedicines, Inc. (NASDAQ:GENB) closed at $15.18 USD, gaining $0.81 (5.60%) from the previous close of $14.37. The stock is currently within 5% of its 52-week high $11.00 and $15.89. With a market capitalization of about $1.93 billion, Generate Biomedicines, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.00). Key stats such as the average daily volume over the past year has been around 576.56 thousand shares, volume is running light vs its 52-week average. Headquartered in Somerville, MA, Generate Biomedicines, Inc. operates in the Financial Services sector and the Asset Management industry. Led by CEO Michael T. Nally, the company employs approximately 312 people and listed since February 27, 2026. Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States.

Technical Performance

Average 10-day trading volume of 299.82 thousand shares is below the 3-month average of 446.35 thousand, indicating normal recent market interest.

Valuation Metrics

Generate Biomedicines, Inc. trades at a P/E ratio of -3.55, slightly below the S&P 500 average, with a price-to-sales ratio of 57.58 and a price-to-book ratio of -1.17 indicating negative book value, which may reflect financial stress. The P/FCF stands at -9.0, also below market averages.

Dividend & Fair Value

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Earnings & Analyst Outlook

Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $30.00 to $16.00. The high target offers 108.77% upside. The low target suggests 11.34% downside. The mean target is $23.50. This offers 63.54% upside. Generate Biomedicines, Inc. earnings surprise history is a mixed track record. The quarter that ended May 07, 2026, missed forecasts by 110.63%.

Financial & Profitability Overview

Over the trailing twelve months, Generate Biomedicines has not generated any revenue.
On valuation metrics, Generate Biomedicines trades at a P/E of -3.55, P/S of 57.58 and P/B of -1.17. The current ratio is 2.85 and quick ratio is 2.85. Debt-to-equity is -0.11, supported by a cash flow-to-debt ratio of -2.93.

Price Forecast & Outlook

Our AI price prediction model suggests that Generate Biomedicines, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 3.62%, with price expected at $14.89 by May 25, 2026, within a range of $14.00 to $15.81 3-Month Outlook: Projected rise of 12.11%, reaching $16.11 by August 07, 2026, with a range of $16.04 to $16.17. 1-Year Outlook: Projected gain of 137.72%, with price at $34.16 by May 11, 2027, within a range of $34.01 to $34.35.

Key Takeaways

Valuation shows Generate Biomedicines, Inc. trading at a premium to the broader market with a P/E of -3.55. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $23.50, suggesting 63.54% upside. Our AI forecast model points to short-term strength (3.62% over two weeks), a medium-term rise (12.11% over three months), and a longer-term gain (137.72% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Generate Biomedicines, Inc. (GENB) stock price?

Generate Biomedicines, Inc. (NASDAQ: GENB) stock price is $15.18 in the last trading session. During the trading session, GENB stock reached the peak price of $15.63 while $14.42 was the lowest point it dropped to. The percentage change in GENB stock occurred in the recent session was 5.6% while the dollar amount for the price change in GENB stock was $0.81.

GENB's industry and sector of operation?

The NASDAQ listed GENB is part of Asset Management industry that operates in the broader Financial Services sector. Generate Biomedicines, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of GENB?

No Data

How GENB did perform over past 52-week?

GENB's closing price is 30.64% higher than its 52-week low of $11.00 where as its distance from 52-week high of $15.89 is -9.57%.

How many employees does GENB have?

Number of GENB employees currently stands at 312.

Link for GENB official website?

Official Website of GENB is: https://generatebiomedicines.com

How do I contact GENB?

GENB could be contacted at phone 188 846 90055 and can also be accessed through its website. GENB operates from 101 South Street, Somerville, MA 02143, United States.

How many shares of GENB are traded daily?

GENB stock volume for the day was 147.16K shares. The average number of GENB shares traded daily for last 3 months was 576.56K.

What is the market cap of GENB currently?

The market value of GENB currently stands at $1.93B with its latest stock price at $15.18 and 127.45M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	312
Beta	0
Sales or Revenue	N/A
5Y Sales Change%	N/A
Fiscal Year Ends	N/A
Sector	Financial Services
Industry	Asset Management

GENB Company Profile and Key Details

Generate Biomedicines

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Key Takeaways

Price Forecast & Outlook

Valuation Metrics